In collaboration with the National Heart, Lung, and Blood Institute, researchers from the Perelman School of Medicine at the University of Pennsylvania led a multicenter, randomized, double-blind, placebo-controlled study that compared the effect of adalimumab treatment of moderate to severe psoriasis or phototherapy on vascular inflammation and cardiovascular biomarkers.
In collaboration with the National Heart, Lung, and Blood Institute, researchers from the Perelman School of Medicine at the University of Pennsylvania led a multicenter, randomized, double-blind, placebo-controlled study that compared the effect of adalimumab to treat moderate to severe psoriasis with phototherapy on vascular inflammation and cardiovascular biomarkers.
Psoriasis is a common chronic inflammatory skin disease that affects more than 125 million people worldwide. Similar to other inflammatory diseases, psoriasis has been associated with increased risk of adverse cardiovascular events, dyslipidemia, and mortality.
Adalimumab is a monoclonal antibody that blocks anti—tumor necrosis factor (anti-TNF) and is the current standard of care biological therapy for the treatment of moderate to severe psoriasis. The therapy has also been suggested to reduce cardiovascular events. In addition, narrowband ultraviolet B phototherapy is also highly effective in the treatment of psoriasis but has not been associated with clinically significant changes in systemic immune function.
The study was a randomized controlled trial that enrolled 97 patients across 8 health centers in the United States with a 1:1:1 match to subcutaneous adalimumab injections every 2 weeks, narrowband ultraviolet B phototherapy at baseline, or placebo. In total, 92 patients (95%) completed the 12-week controlled portion of the study, after which, 81 patients entered into an open-label extension.
During this phase, study participants were treated with adalimumab for 52 weeks (if initially assigned to placebo or phototherapy) or an additional 40 weeks if originally assigned to the adalimumab arm, so that all patients received a total of 52 consecutive weeks of adalimumab therapy. In total, 9 patients (11%) discontinued the study, resulting in 67 patients included in the analysis.
Researchers found that both adalimumab and phototherapy resulted in substantial improvements in psoriasis severity compared with placebo. Patients evaluated during the open-label extension period achieved a high skin clearance rate, with 53% of patients presenting with either clear or almost clear skin.
“These results are similar to prior clinical trials which showed adalimumab did not reduce aortic inflammation in patients with psoriasis. They are, however, in contrast to a previous study which showed an improvement in aortic vascular inflammation at 12 weeks in patients taking ustekinumab— a biologic that targets a different aspect of the immune system,” study author Joel Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania, said in a statement.
Overall, adalimumab reduced key markers of inflammation including glycoprotein acetylation compared with phototherapy. However, larger studies with more detailed phenotyping of vascular disease should be conducted to assess the differences in the effects of adalimumab and phototherapy demonstrated in this trial.
Reference
Mehta N, Shin D, Joshi A, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers. Circ Cardiovasc Imaging. 2018;11(6):e007394. circimaging.ahajournals.org/content/11/6/e007394#sec-9 Accessed May 29, 2018.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Survey Finds Korean Oncologists Trust Biosimilars But Prescribe Originators More
May 13th 2024A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.